Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis

dc.contributor.author Baniandrés-Rodríguez, Ofelia
dc.contributor.author Ferran Farrés, Marta
dc.contributor.author García-Doval, Ignacio
dc.contributor.author Biobadaderm Study Group
dc.date.accessioned 2022-02-22T08:03:40Z
dc.date.available 2022-02-22T08:03:40Z
dc.date.issued 2021
dc.format.mimetype application/pdf
dc.identifier.citation Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis. J Am Acad Dermatol. 2021 Feb; 84(2): 513-7. DOI: 10.1016/j.jaad.2020.10.046
dc.identifier.doi http://dx.doi.org/10.1016/j.jaad.2020.10.046
dc.identifier.issn 0190-9622
dc.identifier.uri http://hdl.handle.net/10230/52538
dc.language.iso eng
dc.publisher Elsevier
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.subject.other COVID-19 (Malaltia)
dc.subject.other Psoriasi -- Tractament
dc.title Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/acceptedVersion

Col·leccions